Nanomedicine and Spleen-Targeting Strategies for Precision Immunomodulation: Advances, Challenges, and Future Perspectives
Source abstract
Abstract
The spleen, which is the largest lymphoid organ, contains various immune cells and plays a crucial role in immunological responses. Because nanoparticles have a natural characteristic of being taken up by reticuloendothelial system (RES) organs, including the spleen, various spleen-targeting nanomedicine strategies have been developed for immunomodulatory therapies. Herein, we review the biological role of the spleen as part of the immune system, types of spleen-targeting nanoparticles, considerations for engineering both current and innovative spleen-targeting strategies, and their therapeutic potential in various diseases, including tumors and autoimmune diseases. Furthermore, we discuss the importance of systems immunology based approaches, including spatial transcriptomics, in achieving a comprehensive understanding of spleen-targeting strategies using nanomedicine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Orthopedic Infections and Treatments · COVID-19 Impact on Reproduction · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Applied Bioengineering, Graduate School of Convergence Science and Technology
Seoul National University
Precision Vaccines Program, Department of Pediatrics
Boston Children’s Hospital
Harvard Medical School
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology
Department of Nuclear Medicine, Union Hospital, Tongji Medical College
Huazhong University of Science and Technology
Hubei Key Laboratory of Molecular Imaging
Cancer Research Institute
Research Institute for Convergence Science
Funding
Korea Health Industry Development Institute · Ministry of Health and Welfare · Ministry of Science and ICT, South Korea · National Research Foundation of Korea · Ministry of Trade, Industry and Energy · National Key Research and Development Program of China Stem Cell and Translational Research · National Natural Science Foundation of China · Korea Evaluation Institute of Industrial Technology · Vaccine Adjuvant Discovery Program
References (100+)
Show source-provided references
1. 10.1038/nri183910.1038/nri1839 ↗
2. 10.1056/NEJMra99336010.1056/NEJMra993360 ↗
3. Saroj P. · J. Adv. Sci. Res. · 2012 · 3 · 7
4. 10.1016/j.cyto.2017.04.01210.1016/j.cyto.2017.04.012 ↗
5. 10.1038/nature0860410.1038/nature08604 ↗
6. 10.1038/s44222-022-00016-210.1038/s44222-022-00016-2 ↗
7. 10.1001/jama.1997.0355022021402710.1001/jama.1997.03550220214027 ↗
8. 10.1038/nrclinonc.2016.6510.1038/nrclinonc.2016.65 ↗
9. 10.1016/S2213-2600(20)30226-510.1016/S2213-2600(20)30226-5 ↗
10. 10.1038/s41571-019-0218-010.1038/s41571-019-0218-0 ↗
11. 10.1056/NEJMra202613110.1056/NEJMra2026131 ↗
12. 10.1016/j.jconrel.2022.04.00510.1016/j.jconrel.2022.04.005 ↗
13. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
14. 10.1126/sciadv.abe785310.1126/sciadv.abe7853 ↗
15. 10.1016/j.jconrel.2019.09.01810.1016/j.jconrel.2019.09.018 ↗
16. 10.3389/fimmu.2023.129749310.3389/fimmu.2023.1297493 ↗
17. 10.1146/annurev-chembioeng-080615-03444610.1146/annurev-chembioeng-080615-034446 ↗
18. 10.1021/jacs.4c0626710.1021/jacs.4c06267 ↗
19. 10.1126/sciimmunol.aau608510.1126/sciimmunol.aau6085 ↗
20. 10.1016/j.nantod.2023.10194310.1016/j.nantod.2023.101943 ↗
21. 10.1038/s41565-020-00810-210.1038/s41565-020-00810-2 ↗
22. 10.1002/adfm.20241710110.1002/adfm.202417101 ↗
23. 10.1007/s13346-016-0304-010.1007/s13346-016-0304-0 ↗
24. 10.1016/j.addr.2022.11441710.1016/j.addr.2022.114417 ↗
25. 10.1016/j.immuni.2013.10.01010.1016/j.immuni.2013.10.010 ↗
26. 10.1007/BF0030452410.1007/BF00304524 ↗
27. 10.1016/0304-4165(93)90105-H10.1016/0304-4165(93)90105-H ↗
28. 10.1016/0005-2760(92)90228-N10.1016/0005-2760(92)90228-N ↗
29. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
30. 10.1182/blood-2014-02-55383410.1182/blood-2014-02-553834 ↗
31. 10.1038/nri166910.1038/nri1669 ↗
32. 10.1038/srep2587610.1038/srep25876 ↗
33. 10.3389/fphar.2015.0028610.3389/fphar.2015.00286 ↗
34. 10.1016/j.heliyon.2022.e0939410.1016/j.heliyon.2022.e09394 ↗
35. 10.1126/sciadv.abi632610.1126/sciadv.abi6326 ↗
36. 10.1021/acsnano.2c0889810.1021/acsnano.2c08898 ↗
37. 10.1038/nature1830010.1038/nature18300 ↗
38. 10.1038/s41586-020-2537-910.1038/s41586-020-2537-9 ↗
39. 10.2741/314910.2741/3149 ↗
40. 10.1016/j.bbmt.2010.11.02210.1016/j.bbmt.2010.11.022 ↗
41. 10.1182/blood-2020-14152610.1182/blood-2020-141526 ↗
42. 10.1038/s41578-023-00581-x10.1038/s41578-023-00581-x ↗
43. 10.1016/j.addr.2021.11408310.1016/j.addr.2021.114083 ↗
44. 10.1016/j.smim.2018.05.00110.1016/j.smim.2018.05.001 ↗
45. 10.7150/thno.7725910.7150/thno.77259 ↗
46. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
47. 10.1073/pnas.181127611510.1073/pnas.1811276115 ↗
48. 10.1016/j.jconrel.2021.01.00510.1016/j.jconrel.2021.01.005 ↗
49. 10.1016/j.jconrel.2019.09.00910.1016/j.jconrel.2019.09.009 ↗
50. 10.1016/j.jconrel.2023.03.05210.1016/j.jconrel.2023.03.052 ↗
51. 10.1016/j.addr.2022.11441710.1016/j.addr.2022.114417 ↗
52. 10.3390/ph1508101710.3390/ph15081017 ↗
53. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
54. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
55. 10.1002/adma.20220497610.1002/adma.202204976 ↗
56. 10.1038/s41551-023-01050-010.1038/s41551-023-01050-0 ↗
57. 10.1038/s41467-019-12275-610.1038/s41467-019-12275-6 ↗
58. 10.1016/j.jare.2021.11.00810.1016/j.jare.2021.11.008 ↗
59. 10.3390/app1219947910.3390/app12199479 ↗
60. 10.1016/j.jconrel.2019.02.02510.1016/j.jconrel.2019.02.025 ↗
61. 10.1021/acsnano.6b0645110.1021/acsnano.6b06451 ↗
62. 10.1038/s41467-021-27945-710.1038/s41467-021-27945-7 ↗
63. 10.1021/acsomega.2c0540710.1021/acsomega.2c05407 ↗
64. 10.3390/pharmaceutics1412280810.3390/pharmaceutics14122808 ↗
65. 10.1016/j.actbio.2021.06.02310.1016/j.actbio.2021.06.023 ↗
66. 10.1038/nbt.333010.1038/nbt.3330 ↗
67. 10.1016/j.ymthe.2017.12.01810.1016/j.ymthe.2017.12.018 ↗
68. 10.1021/acs.biomac.7b0099510.1021/acs.biomac.7b00995 ↗
69. 10.1038/nbt134010.1038/nbt1340 ↗
70. 10.1016/j.jconrel.2011.09.09810.1016/j.jconrel.2011.09.098 ↗
71. 10.1146/annurev-pharmtox-010611-13462310.1146/annurev-pharmtox-010611-134623 ↗
72. 10.1002/jemt.2040810.1002/jemt.20408 ↗
73. 10.1016/j.ejpb.2007.08.00110.1016/j.ejpb.2007.08.001 ↗
74. 10.1021/bc100070g10.1021/bc100070g ↗
75. 10.1038/nmat378010.1038/nmat3780 ↗
76. 10.1016/j.colsurfb.2008.07.00410.1016/j.colsurfb.2008.07.004 ↗
77. 10.1016/j.biomaterials.2010.07.04510.1016/j.biomaterials.2010.07.045 ↗
78. 10.1039/C5NR03626G10.1039/C5NR03626G ↗
79. 10.1016/j.jconrel.2024.05.00710.1016/j.jconrel.2024.05.007 ↗
80. 10.1016/j.jconrel.2022.03.04810.1016/j.jconrel.2022.03.048 ↗
81. 10.1016/j.jconrel.2022.03.04610.1016/j.jconrel.2022.03.046 ↗
82. 10.1016/j.addr.2016.01.02210.1016/j.addr.2016.01.022 ↗
83. 10.1039/D0BM01609H10.1039/D0BM01609H ↗
84. 10.1002/adma.20230168610.1002/adma.202301686 ↗
85. 10.1021/acsami.3c0049410.1021/acsami.3c00494 ↗
86. 10.1186/s12951-022-01730-010.1186/s12951-022-01730-0 ↗
87. 10.15252/emmm.20221683610.15252/emmm.202216836 ↗
88. 10.1021/jacs.4c0045110.1021/jacs.4c00451 ↗
89. 10.1038/s41392-023-01452-110.1038/s41392-023-01452-1 ↗
90. 10.1038/s12276-023-01068-z10.1038/s12276-023-01068-z ↗
91. 10.1016/j.colsurfb.2015.08.03710.1016/j.colsurfb.2015.08.037 ↗
92. 10.1016/j.jconrel.2018.06.00110.1016/j.jconrel.2018.06.001 ↗
93. 10.1038/s41423-021-00726-410.1038/s41423-021-00726-4 ↗
94. 10.1023/A:102055831716210.1023/A:1020558317162 ↗
95. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
96. 10.1038/s41577-023-00857-x10.1038/s41577-023-00857-x ↗
97. 10.1021/acsnano.8b0096610.1021/acsnano.8b00966 ↗
98. 10.1073/pnas.140868611110.1073/pnas.1408686111 ↗
99. 10.1021/acsnano.8b0162510.1021/acsnano.8b01625 ↗
100. 10.1002/adma.20160694410.1002/adma.201606944 ↗